Enforcement Report - Week of November 8, 2023
Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis
SAN FRANCISCO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced multiple data presentations for AT-01 (iodine (I-124) evuzamitide), the company’s pan-amyloid binding peptide in development as an amyloid-specific imaging agent for the diagnosis and management of all types of systemic amyloidosis. These data were included in poster presentations at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany as well as the American Society of Nuclear Cardiology (ASNC) taking place September 8-11, 2022, in Orlando, Florida.
BELLEVUE, Wash.--(BUSINESS WIRE)--Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced that its wholly owned subsidiary, Novo Healthnet Limited, has been granted a Natural Product Number (NPN) by Health Canada for IoNovo Iodine, a proprietary pure aqueous iodine micronutrient delivered in an oral or nasal spray format for maximum impact and bioavailability. An NPN is a product license assessed and granted by Health Canada to commercialize a product that is found to be safe, effective, and of high quality.
BELLEVUE, Wash.--(BUSINESS WIRE)--Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced that its wholly owned subsidiary, Novo Healthnet Limited, has been granted a Natural Product Number (NPN) by Health Canada for IoNovo Iodine, a proprietary pure aqueous iodine micronutrient delivered in an oral or nasal spray format for maximum impact and bioavailability. An NPN is a product license assessed and granted by Health Canada to commercialize a product that is found to be safe, effective, and of high quality.
A radiopharmaceuticals plant is the most likely source of the radioactive iodine-131 detected in several countries in recent weeks according to experts.
Vitalah® is committed to providing the highest quality dietary supplements, and part of that commitment is ensuring that each formulation includes the safest, most efficacious ingredients on the market. That's why Vitalah recently made three upgrades to its Adult Oxylent® formula: switching the source of folate from folic acid to 5-MTHF (5-methyltetrahydrofolate); changing the source of iodine from potassium iodide to kelp; and adding in sources of vitamins A and E.
BioPharmX Corporation (NYSE MKT: BPMX), specialty pharmaceutical company developing products for use in dermatology and women's health, today announced Health Canada has approved the Canadian expansion of a Phase 4 study of the company's Violet® molecular iodine supplement for fibrocystic breast condition (FBC) and cyclic mastalgia. Last month, the Food and Drug Administration approved the study in the United States.